-
Recent Posts
- December 01 2013 – Human stem cells converted to functional lung cells
- November 30 2013 – Keyhole lung transplant performed on 60-year-old in Chennai
- November 27 2013 – FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019
- November 15 2013 – Enzo Biochem Announces Study in Leading Scientific Journal Linking Idiopathic Pulmonary Fibrosis, a Deadly Human Disease with No Effective Treatment Options, to Presence of a Monkey Virus
- November 10 2013 – Research by Saint Louis University scientists offers way to disrupt fibrosis
Recent Comments
- Fish With Captain Frank on June 20 2012 MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)
- Raymond on June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Johng182 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- Johnf73 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- extreme rush on June 28 2012 Grasping at Straws while Gasping for Air
Archives
Categories
Meta
Monthly Archives: November 2013
October 9 2013- Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis
Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
1 Comment
October 3 2013 – Newly identified biomarkers help predict outcome in deadly lung disease
New Haven, Conn. – A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science Translational … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
September 29 2013 – Trial to determine if stem cells can help with rare lung disease
By Cindy Krischer Goodman cindykgoodman@gmail.com Jose Guzman began gasping for breath while using his treadmill on the lowest setting and knew something was wrong. His search for answers led him to the diagnosis of a rare lung disease with no … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
September 28 2013 – Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
Abstract During the past decade important progress has been made regarding the pathogenesis of idiopathic pulmonary fibrosis (IPF), which is the most devastating form of idiopathic interstitial pneumonia with a median survival of 3 years. The knowledge gained has been … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, www.ipftoday.com
Leave a comment
